Improving Affordability of Pharmaceutical Treatments for Diabetes: A Call for Action
Unaffordability of pharmaceutical treatments remains as a critical barrier to diabetes care in the U.S. Through a synthesis of recent evidence on affordability of diabetes drugs, with particular attention to emergent reforms, this call for action focuses on structural solutions to improve the affordability of pharmaceutical treatments for diabetes in the U.S. that providers should be aware of and consider supporting. Incentivizing competition in biosimilars and generics markets, increasing transparency, reforming pricing models that influence drug coverage, and expanding federal negotiation of drug prices, among other actions, can help make prescription drugs more affordable for patients, reduce budgetary impacts on payors, and increase access, ultimately helping to improve the health of all Americans living with diabetes.
Authors
- Kelly E. Anderson (ORCID: https://orcid.org/0000-0002-1471-6283)
- Michael DiStefano
- Jeromie Ballreich (ORCID: https://orcid.org/0000-0003-2564-4577)
- Mariana P. Socal (ORCID: https://orcid.org/0000-0001-9459-4898)
- J. M. S. O.
- Fernando Gerchman (ORCID: https://orcid.org/0000-0001-5873-9498)
- Joseph Levy (ORCID: https://orcid.org/0000-0002-9317-5306)
- Namratha R. Kandula (ORCID: https://orcid.org/0000-0003-2570-3426)
- Ilina C. Odouard (ORCID: https://orcid.org/0009-0006-5431-3979)
- Pineal I. Bareamichael
- Soyeon Kang (ORCID: https://orcid.org/0000-0003-0049-2490)
Institutions
- Northwestern University (US)
- Universidade Federal do Rio Grande do Sul (BR)
- Johns Hopkins University (US)
- William Carey University (US)
- Georgetown University (US)
- Johns Hopkins Medicine (US)
- University of Colorado Anschutz Medical Campus (US)
- University of Montana (US)
Publication Details
- Journal
- Diabetes Care
- Published
- 2025-06-21
- DOI
- https://doi.org/10.2337/dci25-0002
- Citations
- 1
- Primary Topic
- Pharmaceutical Economics and Policy
- Type
- article
- Field-Weighted Citation Impact
- 3.13
Funders
- U.S. Department of Defense
- American Diabetes Association
- American Heart Association
- Arnold Ventures
- Agency for Healthcare Research and Quality
- Uniformed Services University of the Health Sciences
- Defense Health Agency
- National Heart, Lung, and Blood Institute
- National Institute on Minority Health and Health Disparities